Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Predictors of disease activity in 857 patients with MS treated with interferon beta-1b.
Association between multiple sclerosis and chronic periodontitis: a population-based pilot study.
Client-centred therapy in multiple sclerosis: More intensive diagnostic evaluation and less intensive treatment.
MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T.
Multiple sclerosis: a primary care perspective.
Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansions of C9ORF72.
Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: Relationship to oxidative stress.
Safety and efficacy of fingolimod in treatment-naïve multiple sclerosis patients.
Motor programme activating therapy influences adaptive brain functions in multiple sclerosis: clinical and MRI study.
Interpretation and visualization of non-linear data fusion in kernel space: study on metabolomic characterization of progression of multiple sclerosis.
Administration of low dose-estrogen attenuates persistent inflammation, promotes angiogenesis and improves locomotor function following chronic spinal cord injury in rats.
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy.
Evaluation of oxidative and nitrosative stress in relapsing remitting multiple sclerosis: effect of corticosteroid therapy.
CCSVI and MS: no meaning, no fact.
Over six cups of coffee a day may reduce the risk of developing multiple sclerosis.
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia.
Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.
Recent Gains in Clinical Multiple Sclerosis Research Review.
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity.
The King-Devick (K-D) test of rapid eye movements: A bedside correlate of disability and quality of life in MS.
Minocin
Treatment of human spasticity with delta 9-tetrahydrocannabinol.
The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes.
Progenitor-derived Oligodendrocyte Culture System from Human Fetal Brain.

Pages